Recent pages

Company Name

S/Santarus (SNTS)

Edit
page

New
page

Print
page

This page was last modified over a year ago by Sysop

Santarus (SNTS)

This is an EDITABLE stock research wiki. You can contribute by clicking on the EDIT PAGE link above or on the page icons that appear when you roll over one of the category subtitles below.

From 1

1. Company Information:
2. Company Overview:

2.1. Company Products/Services/Markets:
2.2. Strategy:
2.3. Competitors:
2.4. Industry Trends and News:
2.5. Acquisitions, Divestitures, Major Transactions, Spin-offs :
2.6. Management – Pros & Cons, Changes:

5.1. Buy Rationale:
5.2. Sell Rationale:

6. Projected Financials:
7. Discussion:
8. Footnotes:
9. News:
10. See Also (links to blogs, forums, external sources, etc...):

Company Information:

Company Address:

10590 West Ocean Air Drive

Suite 200

San Diego, CA 92130-4682

Company’s Web Address: http://www.santarus.com/

Industry Sector:

Fiscal Year:

Dividend:

Note: this section is not editable. Please click here to report any inaccuracies.

Shares Outstanding: 50,700,000
Market Capitalization: Updating...

Income Statements
Click for: Annual Income Statement
Click for: Quarterly Income Statement

Balance Sheets
Click for: Annual Balance Sheet
Click for: Quarterly Balance Sheet

Cash Flow Statements
Click for: Annual Cash Flow Statement
Click for: Quarterly Cash Flow Statement

SEC Filings
Click for: Form 10-Ks
Click for: Form 10-Qs
Click for: Annual Proxy Statements
Link to SEC filings search: http://www.sec.gov/cgi-bin/srch-edgar

Company Overview:

Note: this section is not editable.

Founded in 1996, Santarus Inc. is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of proprietary products and therapies that have the potential to treat gastrointestinal diseases and disorders, including gastroesophageal reflux disease (GERD). The company's main focus lies on the commercialization of proprietary immediate-release proton pump inhibitor (PPI) products. PPIs are the most frequently prescribed drugs for the treatment of many upper gastrointestinal (GI) diseases and disorders. Santarus offers the Zegerid family of products, which are proprietary immediate-release formulations that combine omeprazole, a PPI, and one or more antacids. These products are approved by the FDA for the treatment or reduction of the risk of a variety of upper GI diseases and disorders. Zegerid is currently marketed in capsule and powder for oral suspension dosage forms.

In 2007, Santarus earned $94.4 million in revenue, 84% of which came from product sales. Other revenues accounted for the balance. Santarus has licensing agreements with two major pharmaceutical companies, Schering-Plough and GlaxoSmithKline, for Zegerid. Besides this, the company has co-promotion agreements for two products Glumetza and the EZ-Prep Bowel Cleansing system. Headquartered in San Diego, California, Santarus currently employs 337 people.

Read full report on Santarus, Inc.

Company overview provided by

Company Products/Services/Markets:

Enter Company Products/Services Here

Strategy:

Describe Key Aspects of Company's Strategy Here

Competitors:

Enter Competitors Here

Industry Trends and News:

Enter Industry Trends and News Here

Acquisitions, Divestitures, Major Transactions, Spin-offs :

Enter Acquisitions, Divestiures, Major Transactions, Spin-offs Here

Management – Pros & Cons, Changes:

Enter Management - Pros & Cons, Changes Here

Financial Analysis:

Enter Financial Analysis Here

Valuation:

Enter Valuation Analysis and Valuation Ratios Here

	2007	2006	2005
Price/Earnings
Price/EBITDA
Price/Pre-tax Income
Price/Revenue

Investment Rationale:

Buy Rationale:

Enter Buy Rationale Here

Sell Rationale:

Enter Sell Rationale Here

Projected Financials:

Income Statement: (Paste Here)

Balance Sheet: (Paste Here)

Cash Flow Statement: (Paste Here)

Financial Ratios: (Paste Here)

Other: (Paste Here)

Discussion:

This area is for debates regarding different recommendations for this stock.

Footnotes:

News:

Yahoo! Finance Blog
Getting the most out of the Interactive Chart If you’ve clicked the thumbnail chart — or a time period link below it — on our quote page, you’ve likely visited our Interactive Chart. The Interactive Chart is a relatively new addition to Yahoo! Finance; it became generally available in April. There are several things you can do on the Interactive Chart that you [...]
Real-Time ECN Quotes Are Now Available on Multi-Quote and Portfolios Pages! Thanks to everyone for the great feedback on our recent real-time features on Yahoo! Finance. We know this is information you value, so today we’re pleased to build on our real-time features with the addition of Real-Time ECN views in multi-quote and portfolio pages on Yahoo! Finance. With the markets being volatile and earnings right around [...]
Comprehensive Coverage on Commodities Futures on Yahoo! Finance Yahoo! Finance is the industry leader for providing up-to-date information on companies, including free real-time quotes. Did you know that we also provide comprehensive coverage on commodities? Go to http://finance.yahoo.com/futures to discover what’s happening with commodities. With energy prices soaring, energy futures provide insight into where the market thinks energy prices are headed. Precious metals (for [...]
Yahoo! Finance Launched more Real-Time ECN Features Today! Today we are delighted to announce more Real-Time ECN information. We have created a new page that has real-time streaming prices for the bid, bid size, ask, ask size and the top of the book. The top of the book is commonly referred to as Level 2 data and this features the 5 highest bid prices [...]
Yahoo! Finance Launches Free Real-Time ECN Prices We are very excited to announce the availability of free US real-time ECN quotes on Yahoo! Finance. Many of you will remember this was a very popular feature that Yahoo! Finance provided through August 2006 when due to consolidation in the marketplace and a new pricing structure it was removed. We’ve been listening to your feedback [...]